Skip to main content
. 2018 Nov 13;10(11):434. doi: 10.3390/cancers10110434

Figure 1.

Figure 1

Kaplan-Meier curves of the progression-free survival (PFS) (A,C,E,G) and overall survival (OS) (B,D,F,H) of the patients receiving a first-line EGFR TKI, while classified the patients by (A,B) the exon of EGFR mutation, (C,D) the drug sensitivity of EGFR mutation, (E,F) the EGFR TKI used, and (G,H) the age group. Abbreviation: PFS = progression-free survival; OS = overall survival.